MultiCell's toll receptor technology could work against avian flu

By E. Janene Geiss

Philadelphia, Oct. 21 - MultiCell Technologies, Inc. announced Friday that preclinical tests of a subsidiary's toll receptor technology showed it was able to reduce pulmonary virus titers in a strain of the flu similar to avian flu.

In a company news release, officials said MultiCell Immunotherapeutics, Inc.'s toll receptor technology was able to reduce pulmonary virus titers by 1,000-fold in the H1N1 strain of the flu to barely detectable levels.

Because the H1N1 strain contains many of the same proteins as the H5N1, or avian flu, officials said this could be important to understanding how to develop an immunotherapeutic agent against avian flu.

"We believe that these results highlight the commercial opportunities for our immunotherapeutics," Dr. Stephen Chang, president of MultiCell Technologies Inc., said in the release.

Lincoln, R.I.-based MultiCell Technologies develops therapies and supplies immortalized cell lines for drug discovery. Its subsidiary, MultiCell Immunotherapeutics, is focused on commercializing new therapeutics for treatment of diseases and disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.